The University of California scientists have discovered a new targeted therapy drug that can extend the Treatment Duration for individuals with a specific subtype of glioma, a deadly brain tumor. The drug, vorasidenib, was found to more than double the progression-free survival of patients with recurrent grade 2 glioma carrying IDH1 and IDH2 mutations. Compared […]

The post New Drug Extends Treatment Duration For Glioma Patients first appeared on World Pharma Today.